DaVita, Inc. Hits New 52-Week High of $229.75, Showcasing Strong Growth

DaVita, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 229.75 on July 1, 2026. This achievement underscores the stock's impressive performance over the past year, with a remarkable increase of 61.06%, significantly outpacing the S&P 500's growth of 20.74% during the same period. The company's market capitalization stands at USD 11,513 million, reflecting its position within the small-cap category. DaVita's price-to-earnings (P/E) ratio is currently at 11.00, indicating a valuation that may attract attention in the context of its industry. However, the company does not offer a dividend yield, and its debt-to-equity ratio is reported at -15.25, suggesting a unique financial structure. Additionally, the return on equity is notably low at -163.56%, and the price-to-book ratio is at -17.68. As DaVita continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this new high marks a pivotal moment in its stock performance trajectory.